OS Therapies (NYSEAMERICAN:OSTX) Shares Up 3.6% – Here’s Why

OS Therapies Incorporated (NYSEAMERICAN:OSTX) shares shot up 3.6% during mid-day trading on Thursday . The company traded as high as $1.46 and last traded at $1.43. 342,809 shares were traded during mid-day trading, a decline of 27% from the average session volume of 470,165 shares. The stock had previously closed at $1.38.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. D. Boral Capital reissued a “buy” rating and set a $20.00 price target on shares of OS Therapies in a research report on Thursday, February 5th. Zacks Research upgraded shares of OS Therapies from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 11th. Finally, Lake Street Capital dropped their target price on shares of OS Therapies from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, OS Therapies presently has an average rating of “Moderate Buy” and a consensus price target of $18.50.

OS Therapies Stock Up 3.6%

The stock has a market cap of $50.35 million, a P/E ratio of -1.74 and a beta of -3.79. The firm’s 50 day simple moving average is $1.40 and its two-hundred day simple moving average is $1.78.

Hedge Funds Weigh In On OS Therapies

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Susquehanna International Group LLP bought a new position in shares of OS Therapies during the third quarter valued at approximately $29,000. Jane Street Group LLC acquired a new position in OS Therapies during the 4th quarter valued at approximately $39,000. Ground Swell Capital LLC bought a new position in OS Therapies during the 3rd quarter worth $40,000. Mercer Global Advisors Inc. ADV acquired a new stake in OS Therapies in the third quarter worth $40,000. Finally, Bridgeway Capital Management LLC bought a new stake in OS Therapies in the second quarter valued at $47,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.